Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vB_KpP_AttikonH4
- Development stage
- Preclinical
- Lead developer
- Attikon University Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
vB_KpP_AttikonH4 is a lytic bacteriophage belonging to the *Drulisvirus* genus (Podoviridae family) that specifically targets multidrug-resistant (MDR) and carbapenem-resistant *Klebsiella pneumoniae* (CRKP) isolates. It was isolated from influent wastewater samples collected from Athens' central wastewater plant in Psyttaleia by researchers at the Attikon University Hospital in Greece. The phage has been evaluated in preclinical studies, including in vitro combination testing with antibiotics (such as amikacin, meropenem, colistin, and ceftazidime/avibactam) showing phage-antibiotic synergy, and in vivo pharmacokinetic and pharmacodynamic (PK/PD) dose-fractionation studies using murine neutropenic thigh and lung infection models.
- Other names
- AttikonH4AttikonH-4AttikonH 4Klebsiella phage vB_KpP_AttikonH4
Beyond the preview
Go deeper on vB_KpP_AttikonH4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vB_KpP_AttikonH4.